Literature DB >> 19022943

Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.

Gry Vibeke Bakken1, Ida Rudberg, Hege Christensen, Espen Molden, Helge Refsum, Monica Hermann.   

Abstract

The antipsychotic drug quetiapine is extensively metabolized by CYP3A4, but little is known about the possible influence of the polymorphic enzyme CYP3A5. This in vitro study investigated the relative importance of CYP3A4 and CYP3A5 in the metabolism of quetiapine and compared the metabolic pattern by the two enzymes, in the presence or absence of cytochrome b(5). Intrinsic clearance (CL(int)) of quetiapine was determined by the substrate depletion approach in CYP3A4 and CYP3A5 insect cell microsomes with or without coexpressed cytochrome b(5). Formation of the metabolites quetiapine sulfoxide, N-desalkylquetiapine, O-desalkylquetiapine, and 7-hydroxyquetiapine by CYP3A4 and CYP3A5 were compared in the different microsomal preparations. CL(int) of quetiapine by CYP3A5 was less than 35% relative to CYP3A4. CL(int) was higher (3-fold) in CYP3A4 microsomes without cytochrome b(5) compared with CYP3A4 microsomes with coexpressed cytochrome b(5), whereas in CYP3A5 microsomes CL(int) was similar for both microsomal preparations. Metabolism of quetiapine by CYP3A5 revealed a different metabolic pattern compared with CYP3A4. The results indicated that O-desalkylquetiapine constituted a higher proportion of the formed metabolites by CYP3A5 compared with CYP3A4. In conclusion, the present study indicates that CYP3A5 is of minor importance for the overall metabolism of quetiapine, regardless of the presence of cytochrome b(5). However, a different metabolic pattern by CYP3A5 compared with CYP3A4 could possibly result in different pharmacological and/or toxicological effects of quetiapine in patients expressing CYP3A5.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19022943     DOI: 10.1124/dmd.108.023291

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

1.  4β-Hydroxycholesterol level significantly correlates with steady-state serum concentration of the CYP3A4 substrate quetiapine in psychiatric patients.

Authors:  Caroline Gjestad; Tore Haslemo; Ole A Andreassen; Espen Molden
Journal:  Br J Clin Pharmacol       Date:  2017-07-21       Impact factor: 4.335

2.  Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels.

Authors:  Gudrun Hefner; Mohamed E E Shams; Stefan Unterecker; Tanja Falter; Christoph Hiemke
Journal:  Psychopharmacology (Berl)       Date:  2015-06-03       Impact factor: 4.530

3.  Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.

Authors:  Saeed Alqahtani; Amal Kaddoumi
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

Review 4.  Psychotropic drug-drug interactions involving P-glycoprotein.

Authors:  Yumiko Akamine; Norio Yasui-Furukori; Ichiro Ieiri; Tsukasa Uno
Journal:  CNS Drugs       Date:  2012-11       Impact factor: 5.749

5.  Fatal combination of mitragynine and quetiapine - a case report with discussion of a potential herb-drug interaction.

Authors:  Rhome L Hughes
Journal:  Forensic Sci Med Pathol       Date:  2018-11-29       Impact factor: 2.007

6.  A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study.

Authors:  Xiujuan Chen; Chen Liang; Lijun Cui; Jian Le; Zheyuan Qian; Runsheng Zhang; Zhanying Hong; Yifeng Chai
Journal:  J Food Drug Anal       Date:  2018-08-14       Impact factor: 6.157

7.  Recurrent priapism from therapeutic quetiapine.

Authors:  Omeed Saghafi; Amanda Kao; Jeffrey Druck
Journal:  West J Emerg Med       Date:  2014-02

8.  Bioequivalence of two quetiapine extended release tablets in Chinese healthy volunteers under fasting and fed conditions and effects of food on pharmacokinetic profiles.

Authors:  Xiaomei Huang; Suhua Zhang; Yanxia Ma; Heng Yang; Chuan He; Rufang Tian; Han Mei; Lipeng Liu; Bikui Zhang
Journal:  Drug Des Devel Ther       Date:  2018-12-31       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.